NCT06034353Completed
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
Source: ClinicalTrials.gov · Last updated 31 Jan 2025
Brief summary (registry, in English)
The purpose of this interventional study is to assess the impact of pharmacist-led cognitive behavioral intervention in epileptic patients. The main questions are: 1. If pharmacist-led cognitive behavioral therapy can help in improving patient medication adherence? 2. How will the cognitive behavioral therapy impact the quality of life of the patients? Participants of this study will be provided basic or advanced level counselling and educational material as part of their routine pharmacy visit. Researchers will compare the two groups (Basic and advanced) to see which of the two groups are better in term of medication adherence and quality of life.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 385 (actual)
- First submitted
- 2 Sept 2023
- Start date
- 22 Sept 2023
- Primary completion date
- 20 May 2024
- Lead sponsor
- Hamdard University
- Diseases
- Epilepsy
- NCT number
- NCT06034353
What you commit to
- Study type: Interventional
- Participants enrolled: 385
- From 22 Sept 2023 to the primary completion date, 20 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any terminal disease e.g., end stage renal disease
Other
- Pregnant female patients.
- Patients who provide incomplete information
- Patients not willing to participate were excluded from the study.
Who the study is looking for
- Patients with confirmed diagnosis.
- Patients treated for epilepsy with at least one anti epileptic drug, subjects willing to participate in the study with or without other severe co-morbidities were included in the study.
Age in the registry: 15 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shifa International Hospital Coordinator of this site? Confirm its status | Islamabad | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.